Organigram Global (OGI) Income from Continuing Operations (2018 - 2026)
Organigram Global (OGI) posted quarterly Income from Continuing Operations of 13862929.41 for Q1 2026, down 166.04% year-on-year from 20991724.03 in Q1 2025, and down 3766.46% on a QoQ basis from 358543.14 in Q4 2025.
Organigram Global (OGI) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Organigram Global (OGI) has reported Income from Continuing Operations for 7 consecutive years, with 13862929.41 the latest figure, recorded in Q1 2026.
- Quarterly Income from Continuing Operations fell 166.04% year-over-year to 13862929.41 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 24300807.05 (down 72.5% YoY) and the FY2025 annual result came in at 13050970.35, changed N/A from the prior year.
- Income from Continuing Operations slipped to 13862929.41 in Q1 2026 per OGI's latest filing, from 358543.14 in the prior quarter.
- Over the last five years, Income from Continuing Operations for OGI reached as high as 358543.14 in Q4 2025 and fell as low as 13862929.41 in Q1 2026.
- A 3-year average of 6075201.76 and a median of 5039667.25 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2025 — Income from Continuing Operations jumped 92.64% — and 2026, when it sank 166.04%.
- Year by year, Income from Continuing Operations stood at 4868490.0 in 2024, then soared by 92.64% to 358543.14 in 2025, then sank by 3766.46% to 13862929.41 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 13862929.41, 358543.14, and 5210844.49 for Q1 2026, Q4 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 370.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 601.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -3.58 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 274.90 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 176.40 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 197.90 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 57.00 Mn |
| 10 | Organigram Global | 89.89 Mn | 122.96 Mn | 28.97 Mn | -13.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -13.86 Mn |
| Dec 31, 2025 | -358,543.14 |
| Mar 31, 2025 | -5.21 Mn |
| Dec 31, 2024 | -4.87 Mn |
| May 31, 2021 | -104.73 Mn |
| Feb 28, 2021 | 100.73 Mn |
| Nov 30, 2020 | -34.34 Mn |
| Aug 31, 2020 | -170.07 Mn |
| May 31, 2020 | -65.51 Mn |
| Feb 29, 2020 | -6.83 Mn |
| Nov 25, 2019 | 15.25 Mn |
| Aug 31, 2019 | -15.92 Mn |
| May 31, 2019 | -7.05 Mn |
| Feb 28, 2019 | -5.69 Mn |
| Nov 30, 2018 | 29.27 Mn |
| May 31, 2018 | 4.09 Mn |